S1P5-Selective Solid Forms for CNS Modulator Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new solid forms of S1P receptor modulators to address the challenges of preparing safe, effective, and high-quality drug products for treating age-related cognitive decline and dementia, particularly in terms of cardiovascular and immunomodulatory effects.
Innovation Solution
The development of solid forms, including crystalline and amorphous forms, of (1s,3s)-3-(2-(4-((4-chlorobenzyl)oxy)phenyl)-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)-yl)cyclobutane-1-carboxylic acid, which exhibit selective affinity for the S1P5 receptor, offering improved pharmaceutical properties such as ease of handling, storage stability, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If S1P receptor modulators are used to treat age-related cognitive decline, then therapeutic effect on CNS disorders is achieved, but unwanted cardiovascular and immunomodulatory effects occur
Solution Approach 1:
The patent applies local quality by developing solid forms with selective affinity for the S1P5 receptor specifically, rather than non-selective binding to multiple S1P receptors. This selectivity localizes the therapeutic action to the CNS where S1P5 is expressed, while avoiding activation of S1P1 and S1P3 receptors in the cardiovascular system, thereby achieving therapeutic effect without unwanted side effects
2Reliability
If new solid forms of S1P receptor modulators are developed, then pharmaceutical properties such as dissolution profiles and shelf-life are improved, but complexity of formulation development increases
Solution Approach 1:
The patent applies parameter changes by developing multiple solid forms (crystalline forms, amorphous forms, solvates, hydrates) of the S1P5 modulator with different physical and chemical parameters. Each solid form has distinct properties such as dissolution rate, stability, and bioavailability, allowing optimization of pharmaceutical properties for specific therapeutic applications while managing formulation complexity through systematic exploration of solid-state variations
Data Source
AI summary
This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.